File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical role of β-lactam/β-lactamase inhibitor combinations

TitleClinical role of β-lactam/β-lactamase inhibitor combinations
Authors
Issue Date2003
PublisherAdis International Ltd. The Journal's web site is located at http://drugs.adisonline.com/
Citation
Drugs, 2003, v. 63 n. 14, p. 1511-1524 How to Cite?
AbstractThe use of β-lactamase inhibitors in combination with β-lactam antibiotics is currently the most successful strategy to combat a specific resistance mechanism. Their broad spectrum of activity originates from the ability of respective inhibitors to inactivate a wide range of β-lactamases produced by Gram-positive, Gram-negative, anaerobic and even acid-fast pathogens. Clinical experience confirms their effectiveness in the empirical treatment of respiratory, intra-abdominal, and skin and soft tissue infections. There is evidence to suggest that they are efficacious in treating patients with neutropenic fever and nosocomial infections, especially in combination with other agents. β-Lactam/β-lactamase inhibitor combinations are particularly useful against mixed infections. Their role in treating various multi-resistant pathogens such as Acinetobacter species and Stenotrophomonas maltophilia are gaining importance. Although, generally, they do not constitute reliable therapy against extended-spectrum β-lactamase producers, their substitution in place of cephalosporins appears to reduce emergence of the latter pathogens. Similarly, their use may also curtail the emergence of other resistant pathogens such as Clostridium difficile and vancomycin-resistant enterococci. β-Lactam/β-lactamase inhibitor combinations are generally well tolerated and their oral forms provide effective outpatient therapy against many commonly encountered infections. In certain scenarios, they could even be more cost-effective than conventional combination therapies. With the accumulation of so much clinical experience, their role in the management of infections is now becoming more clearly defined.
Persistent Identifierhttp://hdl.handle.net/10722/157363
ISSN
2015 Impact Factor: 4.883
2015 SCImago Journal Rankings: 1.601
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, Nen_US
dc.contributor.authorYuen, KYen_US
dc.contributor.authorKumana, CRen_US
dc.date.accessioned2012-08-08T08:49:21Z-
dc.date.available2012-08-08T08:49:21Z-
dc.date.issued2003en_US
dc.identifier.citationDrugs, 2003, v. 63 n. 14, p. 1511-1524en_US
dc.identifier.issn0012-6667en_US
dc.identifier.urihttp://hdl.handle.net/10722/157363-
dc.description.abstractThe use of β-lactamase inhibitors in combination with β-lactam antibiotics is currently the most successful strategy to combat a specific resistance mechanism. Their broad spectrum of activity originates from the ability of respective inhibitors to inactivate a wide range of β-lactamases produced by Gram-positive, Gram-negative, anaerobic and even acid-fast pathogens. Clinical experience confirms their effectiveness in the empirical treatment of respiratory, intra-abdominal, and skin and soft tissue infections. There is evidence to suggest that they are efficacious in treating patients with neutropenic fever and nosocomial infections, especially in combination with other agents. β-Lactam/β-lactamase inhibitor combinations are particularly useful against mixed infections. Their role in treating various multi-resistant pathogens such as Acinetobacter species and Stenotrophomonas maltophilia are gaining importance. Although, generally, they do not constitute reliable therapy against extended-spectrum β-lactamase producers, their substitution in place of cephalosporins appears to reduce emergence of the latter pathogens. Similarly, their use may also curtail the emergence of other resistant pathogens such as Clostridium difficile and vancomycin-resistant enterococci. β-Lactam/β-lactamase inhibitor combinations are generally well tolerated and their oral forms provide effective outpatient therapy against many commonly encountered infections. In certain scenarios, they could even be more cost-effective than conventional combination therapies. With the accumulation of so much clinical experience, their role in the management of infections is now becoming more clearly defined.en_US
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://drugs.adisonline.com/en_US
dc.relation.ispartofDrugsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAnti-Bacterial Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshCommunicable Diseases - Drug Therapy - Enzymologyen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshEnzyme Inhibitors - Pharmacology - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshBeta-Lactamases - Antagonists & Inhibitors - Metabolismen_US
dc.subject.meshBeta-Lactamsen_US
dc.titleClinical role of β-lactam/β-lactamase inhibitor combinationsen_US
dc.typeArticleen_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2165/00003495-200363140-00006en_US
dc.identifier.pmid12834367-
dc.identifier.scopuseid_2-s2.0-0038443270en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0038443270&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume63en_US
dc.identifier.issue14en_US
dc.identifier.spage1511en_US
dc.identifier.epage1524en_US
dc.identifier.isiWOS:000184334000006-
dc.publisher.placeNew Zealanden_US
dc.identifier.scopusauthoridLee, N=7402722286en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats